Targeted cytotoxic therapy: Adapting a rapidly progressing anticancer paradigm for depletion of persistent HIV-infected cell reservoirs

Current Opinion in HIV and AIDS

Volumn 6, Issue 1, 2011, Pages 80-85

  Berger, Edward A ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

Adoptive cell therapy; Antibody drug conjugates; Chimeric antigen receptor; Immunotoxin; Oncolytic virotherapy; Radioimmunotherapy; Targeted liposome

Indexed keywords

ANTIBODY CONJUGATE; BL 22; GEMTUZUMAB OZOGAMICIN; IBRITUMOMAB TIUXETAN; IMMUNOTOXIN; SCD4 PE40; TOSITUMOMAB I 131; UNCLASSIFIED DRUG; CYTOTOXIN;

ARTICLE; CELL KILLING; CELLULAR IMMUNITY; CYTOTOXICITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER TOXICITY; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; VIROTHERAPY; BIOLOGICAL THERAPY; METHODOLOGY; REVIEW;

BIOLOGICAL THERAPY; CYTOTOXINS; HIV INFECTIONS; HUMANS;

EID: 79954434429     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e3283412515     Document Type: Article

References (50)

1. Shen L, Siliciano RF. Viral reservoirs, residual viremia, and the potential of highly active antiretroviral therapy to eradicate HIV infection. J Allergy Clin Immunol 2008; 122:22-28. (Pubitemid 351899083)
2. Richman DD, Margolis DM, Delaney M, et al. The challenge of finding a cure for HIV infection. Science 2009; 323:1304-1307.
3. Trono D, Van Lint C, Rouzioux C, et al. HIV persistence and the prospect of long-term drug-free remissions for HIV-infected individuals. Science 2010; 329:174-180.
4. Burton DR, Weiss RA. A boost for HIV vaccine design. Science 2010; 329:770-773.
5. Rossi JJ, June CH, Kohn DB. Genetic therapies against HIV. Nat Biotechnol 2007; 25:1444-1454. (Pubitemid 350233141)
6. Strebhardt K, Ullrich A. Paul Ehrlich's magic bullet concept: 100 years of progress. Nat Rev Cancer 2008; 8:473-480. (Pubitemid 351752547)
7. Sharkey RM, Goldenberg DM. Use of antibodies and immunoconjugates for the therapy of more accessible cancers. Adv Drug Delivery Rev 2008; 60:1407-1420.
8. Alley SC, Okeley NM, Senter PD. Antibody-drug conjugates: targeted drug delivery for cancer. Curr Opin Chem Biol 2010; 14:529-537.
9. Stasi R, Evangelista ML, Buccisano F, et al. Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia. Cancer Treat Rev 2008; 34:49-60. (Pubitemid 351168609)
10. Johansson S, Goldenberg DM, Griffiths GL, et al. Elimination of HIV-1 infection by treatment with a doxorubicin-conjugated antienvelope antibody. AIDS 2006; 20:1911-1915. (Pubitemid 44427607)
11. Dearling JLJ, Pedley RB. Technological advances in radioimmunotherapy. Clin Oncol 2007; 19:457-469. (Pubitemid 46995619)
12. Dadachova E, Casadevall A. Radioimmunotherapy of infectious diseases. Sem Nucl Med 2009; 39:146-153.
13. Dadachova E, Patel MC, Toussi S, et al. Targeted killing of virally infected cells by radiolabeled antibodies to viral proteins. PLoS Med 2006; 3:2094-2103. (Pubitemid 44875942)
14. Wong L, Suh DY, Frankel AE. Toxin conjugate therapy of cancer. Sem Oncol 2005; 32:591-595. (Pubitemid 41772687)
15. Pastan I, Hassan R, FitzGerald DJ, Kreitman RJ. Immunotoxin treatment of cancer. Ann Rev Med 2007; 58:221-237. (Pubitemid 46706511)
16. Manoukian G, Hagemeister F. Denileukin diftitox: a novel immunotoxin. Expert Opin Biol Ther 2009; 9:1445-1451.
17. Kreitman RJ, Stetler-Stevenson M, Margulies I, et al. Phase II trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with hairy cell leukemia. J Clin Oncol 2009; 27:2983-2990.
18. Nagata S, Pastan I. Removal of B cell epitopes as a practical approach for reducing the immunogenicity of foreign protein-based therapeutics. Adv Drug Delivery Rev 2009; 61:977-985.
19. Mathew M, Verma RS. Humanized immunotoxins: a new generation of immunotoxins for targeted cancer therapy. Cancer Sci 2009; 100:1359-1365.
20. Berger EA, Moss B, Pastan I. Reconsidering targeted toxins to eliminate HIV infection: You gotta have HAART. Proc Natl Acad Sci U S A 1998; 95:11511-11513. (Pubitemid 28460445)
21. Berger EA, Pastan I. Immunotoxin complementation of HAART to deplete persisting HIV-infected cell reservoirs. PLoS Pathogens 2010; 6:1-6.
22. Ashorn P, Moss B, Weinstein JN, et al. Elimination of infectious human immunodeficiency virus from human T-cell cultures by synergistic action of CD4-Pseudomonas exotoxin and reverse transcriptase inhibitors. Proc Natl Acad Sci U S A 1990; 87:8889-8893. (Pubitemid 120007614)
23. Goldstein H, Pettoello-Mantovani M, Bera TK, et al. Chimeric toxins targeted to the human immunodeficiency virus type 1 envelope glycoprotein augment the in vivo activity of combination antiretroviral therapy in thy/liv-SCID-Hu mice. J Infect Dis 2000; 181:921-926. (Pubitemid 30194474)
24. Berger C, Turtle CJ, Jensen MC, Riddell SR. Adoptive transfer of virus-specific and tumor-specific T cell immunity. Curr Opin Immunol 2009; 21:224-232.
25. Brenner MK, Heslop HE. Adoptive T cell therapy of cancer. Curr Opin Immunol 2010; 22:251-257.
26. Morgan RA, Dudley ME, Rosenberg SA. Adoptive cell therapy: genetic modification to redirect effector cell specificity. Cancer J 2010; 16:336-341.
27. Pule MA, Savoldo B, Myers GD, et al. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med 2008; 14:1264-1270.
28. Kochenderfer JN, Wilson WH, Janik JE, et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically-engineered to recognize CD19. Blood 2010. [Epub ahead of print]
29. Bridgeman JS, Hawkins RE, Hombach AA, et al. Building better chimeric antigen receptors for adoptive T cell therapy. Curr Gene Ther 2010; 10:77-90.
30. Carpenito C, Milone MC, Hassan R, et al. Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proc Natl Acad Sci U S A 2009; 106:3360-3365.
31. Zhao YB, Wang QJ, Yang SC, et al. A herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity. J Immunol 2009; 183: 5563-5574.
32. Buning H, Uckert W, Cichutek K, et al. Do CARs need a driver's license? Adoptive cell therapy with chimeric antigen receptor-redirected T cells has cause serious adverse events. Human Gene Ther 2010; 21:1-4.
33. Hutter G, Nowak D, Mossner M, et al. Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantaion. New Engl J Med 2009; 360:692-698.
34. Perez EE, Wang JB, Miller JC, et al. Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases. Nat Biotechnol 2008; 26:808-816. (Pubitemid 351961450)
35. Holt N, Wang JB, Kim K, et al. Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo. Nat Biotechnol 2010; 28:839-847.
36. Joseph A, Zheng JH, Follenzi A, et al. Lentiviral vectors encoding human immunodeficiency virus type I (HIV-1)-specific T-cell receptor genes efficiently convert peripheral blood CD8 T lymphocytes into cytotoxic T lymphocytes with potent in vitro and in vivo HIV-1-specific inhibitory activity. J Virol 2008; 82:3078-3089. (Pubitemid 351329196)
37. Kitchen SG, Bennett M, Galic Z, et al. Engineering antigen-specific T cells from genetically modified human hematopoietic stem cells in immunodeficient mice. PLoS One 2009; 4:e8208.
38. Varela-Rohena A, Molloy PE, Dunn SM, et al. Control of HIV-1 immune escape byCD8T cells expressing enhanced T-cell receptor. NatMed 2008; 14:1390-1395.
39. Walker RE, Bechtel CM, Natarajan V, et al. Long-term in vivo survival of receptor-modified syngeneic T cells in patients with human immunodeficiency virus infection. Blood 2000; 96:467-474. (Pubitemid 30463364)
40. Mitsuyasu RT, Anton PA, Deeks SG, et al. Prolonged survival and tissue trafficking following adoptive transfer of CD4 zeta gene-modified autologous CD4+ and CD8+ T cells in human immunodeficiency virus-infected subjects. Blood 2000; 96:785-793. (Pubitemid 30616838)
41. Deeks SG, Wagner B, Anton PA, et al. A phase II randomized study of HIVspecific T-cell gene therapy in subjects with undetectable plasma viremia on combination antiretroviral therapy. Mol Ther 2002; 5:788-797. (Pubitemid 34619072)
42. Garcia-Aragoncillo E, Hernandez-Alcoceba R. Design of virotherapy for effective tumor treatment. Curr Opin Mol Ther 2010; 12:403-411.
43. Mebatsion T, Finke S, Weiland F, Conzelmann KK. A CXCR4/CD4 pseudotype rhabdovirus that selectively infects HIV-1 envelope protein-expressing cells. Cell 1997; 90:841-847. (Pubitemid 27381623)
44. Schnell MJ, Johnson JE, Buonocore L, Rose JK. Construction of a novel virus that targets HIV-1-infected cells and controls HIV-1 infection. Cell 1997; 90:849-857. (Pubitemid 27381624)
45. Park SW, Ye ZP, Schubert M, Paik SY. Defective interfering HIV-1 pseudotypes carrying chimeric CD4 protein. J Biochem Mol Biol 2001; 34:566-572.
46. Ye ZP, Harmison GG, Ragheb JA, Schubert M. Targeted infection of HIV-1 Env expressing cells by HIV(CD4/CXCR4) vectors reveals a potential new rationale for HIV-1 mediated down-modulation of CD4. Retrovirology 2005; 2:1-15.
47. Fanciullino R, Ciccolini J. Liposome-encapsulated anticancer drugs: still waiting for the magic bullet? Curr Med Chem 2009; 16:4361-4373.
48. Lanao JM, Briones E, Colino CI. Recent advances in delivery systems for anti-HIV1 therapy. J Drug Target 2007; 15:21-36. (Pubitemid 47161329)
49. Dinoso JB, Rabi SA, Blankson JN, et al. A simian immunodeficiency virusinfected macaque model to study viral reservoirs that persist during highly active antiretroviral therapy. J Virol 2009; 83:9247-9257.
50. North TW, Higgins J, Deere JD, et al. Viral sanctuaries during highly active antiretroviral therapy in a nonhuman primate model for AIDS. J Virol 2010; 84:2913-2922.